CN108699143B - Il-17c的抗体 - Google Patents

Il-17c的抗体 Download PDF

Info

Publication number
CN108699143B
CN108699143B CN201780011965.2A CN201780011965A CN108699143B CN 108699143 B CN108699143 B CN 108699143B CN 201780011965 A CN201780011965 A CN 201780011965A CN 108699143 B CN108699143 B CN 108699143B
Authority
CN
China
Prior art keywords
antibody
seq
leu
ser
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780011965.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699143A (zh
Inventor
J·D·哈斯
J·克拉蒂格
N·E·R·范德格因斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Morphosys GmbH
Original Assignee
Galapagos NV
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV, Morphosys GmbH filed Critical Galapagos NV
Publication of CN108699143A publication Critical patent/CN108699143A/zh
Application granted granted Critical
Publication of CN108699143B publication Critical patent/CN108699143B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780011965.2A 2016-02-19 2017-02-17 Il-17c的抗体 Active CN108699143B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16156582.5 2016-02-19
EP16156582 2016-02-19
EP16156651.8 2016-02-22
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (en) 2016-02-19 2017-02-17 Antibodies for il-17c

Publications (2)

Publication Number Publication Date
CN108699143A CN108699143A (zh) 2018-10-23
CN108699143B true CN108699143B (zh) 2021-11-09

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780011965.2A Active CN108699143B (zh) 2016-02-19 2017-02-17 Il-17c的抗体

Country Status (33)

Country Link
US (5) US20190048071A1 (https=)
EP (1) EP3416983B1 (https=)
JP (2) JP6535139B2 (https=)
KR (1) KR102715157B1 (https=)
CN (1) CN108699143B (https=)
AU (1) AU2017219837B2 (https=)
BR (1) BR112018016798A2 (https=)
CA (1) CA3014842A1 (https=)
CL (1) CL2018002340A1 (https=)
CO (1) CO2018008724A2 (https=)
CU (1) CU20180087A7 (https=)
CY (1) CY1124296T1 (https=)
DK (1) DK3416983T3 (https=)
EA (1) EA037813B1 (https=)
EC (1) ECSP18070641A (https=)
ES (1) ES2877376T3 (https=)
HR (1) HRP20211059T1 (https=)
HU (1) HUE054755T2 (https=)
IL (1) IL260733B2 (https=)
LT (1) LT3416983T (https=)
MA (2) MA44227B1 (https=)
MD (1) MD3416983T2 (https=)
MX (1) MX2018009860A (https=)
PH (1) PH12018501739A1 (https=)
PL (1) PL3416983T3 (https=)
RS (1) RS62012B1 (https=)
SG (1) SG11201806161TA (https=)
SI (1) SI3416983T1 (https=)
SM (1) SMT202100361T1 (https=)
TN (1) TN2018000289A1 (https=)
TW (1) TW201734041A (https=)
WO (1) WO2017140831A1 (https=)
ZA (1) ZA201806249B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604566B2 (en) * 2015-10-05 2020-03-31 Galapagos Nv Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
HRP20211059T1 (hr) * 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c
TW201919698A (zh) * 2017-09-25 2019-06-01 德商莫菲西斯公司 異位性皮炎之治療
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography
EP4061825A1 (en) * 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060127A3 (en) * 1998-05-15 2000-01-27 Genentech Inc Il-17 homologous polypeptides and therapeutic uses thereof
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
CN103974976A (zh) * 2011-10-19 2014-08-06 莫佛塞斯公司 用于治疗炎性病症的il17c拮抗剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2005295421A1 (en) 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
EP2064237A2 (en) 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
US20120201821A1 (en) * 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2015521591A (ja) * 2012-06-12 2015-07-30 オレガ・バイオテック Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用
EP3233915B1 (en) * 2014-12-15 2024-08-28 MorphoSys AG Antibodies for il-17c
HRP20211059T1 (hr) 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060127A3 (en) * 1998-05-15 2000-01-27 Genentech Inc Il-17 homologous polypeptides and therapeutic uses thereof
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
CN103974976A (zh) * 2011-10-19 2014-08-06 莫佛塞斯公司 用于治疗炎性病症的il17c拮抗剂

Also Published As

Publication number Publication date
KR20180109977A (ko) 2018-10-08
JP2019511910A (ja) 2019-05-09
RS62012B1 (sr) 2021-07-30
MX2018009860A (es) 2019-03-28
WO2017140831A1 (en) 2017-08-24
LT3416983T (lt) 2021-07-12
ECSP18070641A (es) 2018-10-31
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
US20190202906A1 (en) 2019-07-04
MA44227B1 (fr) 2021-06-30
IL260733B2 (en) 2024-03-01
US10633439B2 (en) 2020-04-28
US10259869B2 (en) 2019-04-16
MA44227A (fr) 2018-12-26
SMT202100361T1 (it) 2021-07-12
EA201891594A1 (ru) 2019-01-31
EP3416983B1 (en) 2021-04-07
US20250074978A1 (en) 2025-03-06
EP3416983A1 (en) 2018-12-26
JP6535139B2 (ja) 2019-06-26
IL260733B1 (en) 2023-11-01
DK3416983T3 (en) 2021-06-21
MD3416983T2 (ro) 2021-08-31
CL2018002340A1 (es) 2018-11-23
CY1124296T1 (el) 2022-11-25
TN2018000289A1 (en) 2020-01-16
PL3416983T3 (pl) 2021-10-25
SG11201806161TA (en) 2018-08-30
KR102715157B1 (ko) 2024-10-10
JP2019162119A (ja) 2019-09-26
CO2018008724A2 (es) 2018-08-31
ES2877376T3 (es) 2021-11-16
AU2017219837B2 (en) 2023-08-17
US11987621B2 (en) 2024-05-21
BR112018016798A2 (en) 2018-12-26
IL260733A (https=) 2018-09-20
HUE054755T2 (hu) 2021-09-28
PH12018501739A1 (en) 2019-06-10
MA43088B1 (fr) 2020-10-28
ZA201806249B (en) 2020-02-26
MA43088A1 (fr) 2019-05-31
SI3416983T1 (sl) 2021-08-31
HRP20211059T1 (hr) 2021-10-01
JP6916834B2 (ja) 2021-08-11
EA037813B1 (ru) 2021-05-24
US20190048071A1 (en) 2019-02-14
CA3014842A1 (en) 2017-08-24
TW201734041A (zh) 2017-10-01
US20180340024A1 (en) 2018-11-29
US20200216529A1 (en) 2020-07-09
AU2017219837A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
CN108699143B (zh) Il-17c的抗体
TWI526223B (zh) 人化ａｘｌ抗體類
JP6865826B2 (ja) インターロイキン１７ａを標的とする抗体、その製造方法及び応用
KR20210096559A (ko) 항IL-23p19 항체 및 이의 용도
MX2014004662A (es) Antagonistas de il17c para el tratamiento de trastornos inlflamatorios.
US10604566B2 (en) Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
HK1259711B (en) Antibodies for il-17c
HK1259711A1 (en) Antibodies for il-17c
HK40009395A (en) Antibodies to il-37

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant